Where can I learn more about this study?
You can find more information about this study on the websites listed below. If more information
about the study results is available, it can also be found here.
> www.clinicaltrials.gov. Once you are on the website, type “NCT02987543”
into the search box and click “Search”.
> http://www.clinicaltrialsregister.eu Once you are on the website, click “Home and
Search”, then type “2016-000300-28” in the search box and click “Search”.
> www.AstraZenecaClinicalTrials.com. Once you are on the website, type “D081DC00007”
into the search box, and click “Find a Study”.
Full Study Title: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety
of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic
Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal
Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
AstraZeneca Protocol Number: D081DC00007
National Clinical Trials number: NCT02987543
EudraCT number: 2016-000300-28
AstraZeneca sponsored this study and has its headquarters in Cambridge, UK.
The phone number for the AstraZeneca Information Center is +1-877-240-9479 and the email is
information.center@astrazeneca.com.
Thank you!
Clinical study participants and their families belong to a large community of people who take
part in clinical research around the world. They help researchers answer important health
questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 2.0 2021_02_04
16 | Clinical Study Results